Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up productionCNBC • 09/21/26
Novo Nordisk Falls 7% as Post-Wegovy Growth Plan Fails to Ease Competition Fears; Eli Lilly Slips, Viking Therapeutics Edges Higher24/7 Wall Street • 09/21/26
5 Stocks In The Spotlight Last Week: Wall Street's Most Accurate Analysts Weigh InBenzinga • 09/21/26
Patients are suing GLP-1 drugmakers over the risk of sudden vision loss. The little-discussed potential risk of popular diabetes and weight-loss drugs is on warning labels outside of the U.S.WSJ • 09/19/26
Can Eli Lilly's Two-Drug Obesity Treatment Justify Its $1 Trillion Valuation?24/7 Wall Street • 09/18/26
U.S. FDA approves Inluriyo (imlunestrant) in combination with Verzenio (abemaciclib) for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancerPRNewsWire • 09/18/26
LLY Stock Down Around 7% in a Month: Buy the Dip or Stay Cautious?Zacks Investment Research • 09/17/26
15 stocks that have grown dividends the most — and nearly all have beaten the S&P 500Market Watch • 09/16/26
Beyond Hype: Twist Bioscience Secures Data Pipeline Role In Eli Lilly TuneLab EcosystemBenzinga • 09/16/26
Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on ItZacks Investment Research • 09/16/26
Eli Lilly's Momentum Looks Unstoppable -- but 1 Factor Could Change EverythingThe Motley Fool • 09/15/26
Eli Lilly Stock Gains as Retatrutide and Foundayo Data Highlight Pipeline StrengthBenzinga • 09/15/26
Lilly to present new data on Foundayo, retatrutide, and eloraTZP at EASD 2026, as it strives to change the course of cardiometabolic healthPRNewsWire • 09/15/26
Eli Lilly and Company (LLY) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/14/26